Inhibition of rhesus monkey airway and cutaneous responses to platelet-activating factor (PAF) (AGEPC) with the anti-PAF agent SRI 63-072.
Previous studies with synthetic platelet-activating factor (PAF) (AGEPC) showed that aerosol challenges in rhesus monkeys resulted in airway responses simulating acute antigen-induced responses and immediate-type skin reactions [1]. The current studies evaluated whether an antagonist of PAF (SRI 63-072) could inhibit the airway and cutaneous reactivity to PAF. Under the conditions of these experiments, the antagonist partially inhibited PAF activity in both experimental systems. Inhibition of endpoint cutaneous reactivity to PAF may be a suitable system for comparing potency of pharmacologic antagonists in primate skin.
D000336:Aerosols; D000818:Animals; D005260:Female; D006969:Hypersensitivity, Immediate / Q000139:chemically induced*; D008253:Macaca mulatta; D008297:Male; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D012129:Respiratory Function Tests; D012137:Respiratory System / Q000187:drug effects*; D012867:Skin / Q000187:drug effects*; D013844:Thiazoles / Q000494:pharmacology*
D000336:Aerosols; D010972:Platelet Activating Factor; D013844:Thiazoles; C049820:SRI 63072